Search

Your search keyword '"Concin, Nicole"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Concin, Nicole" Remove constraint Author: "Concin, Nicole" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
29 results on '"Concin, Nicole"'

Search Results

1. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

2. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

3. Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

4. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

5. Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

6. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

7. Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

8. Supplementary Figure 1 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

9. Supplementary Figure 2 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

11. Data from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

12. Supplementary Table 1 from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

13. Supplementary Figure 1 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

14. Data from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

15. Supplementary Figure 3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

16. Supplementary Tables 1-3, Figure Legends 1-3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

17. Supplementary Figure 2 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

18. Supplementary Table 1 from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

19. Supplementary Tables 1-3, Figure Legends 1-3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

20. Supplementary Figure 3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

21. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

22. Abstract AP15: IDENTIFICATION OF P53 PRIONS AS AN INDEPENDENT PROGNOSTIC MARKER FOR SURVIVAL IN HIGH-GRADE SEROUS OVARIAN CANCER

23. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

24. E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

25. Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer

26. Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer

28. Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo

29. Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitorsin Vivo

Catalog

Books, media, physical & digital resources